MapLight pauses preclinical work to focus on ML-007C-MA for schizophrenia; ADC Therapeutics weighs Zynlonta's future after FDA flags safety concerns in LOTIS-5 trial.
August 14, 2026 10:10 AM EDT
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
⏸️ MapLight Therapeutics pauses preclinical and discovery work: The biotech said it will instead focus its resources on advancing its lead …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
New Taiho, Cullinan data heats up lung cancer drug battle
MapLight Therapeutics' $MPLT stock fell 60%+ after ML-007C-MA's once-daily regimen missed Phase 2 ZEPHYR trial's primary…
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.
MapLight Therapeutics' $MPLT stock fell 60%+ after ML-007C-MA's once-daily regimen missed Phase 2 ZEPHYR trial's primary…
MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication…
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with…
Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger…
